Compare Rekvina Labs with Similar Stocks
Stock DNA
Pharmaceuticals & Drugs
INR 13 Cr (Micro Cap)
NA (Loss Making)
33
0.00%
-0.02
-25.10%
13.19
Total Returns (Price + Dividend) 
Risk Adjusted Returns v/s 
Returns Beta
News

Rekvina Labs Ltd Hits New 52-Week High of Rs.22.31 on 13 Feb 2026
Rekvina Labs Ltd has reached a significant milestone by hitting a new 52-week high of Rs.22.31 today, marking a remarkable rally that has seen the stock gain over 200% in the past 21 trading sessions. This surge underscores a strong momentum in the stock’s price action, outperforming its sector and maintaining a consistent upward trajectory across multiple moving averages.
Read full news article
Rekvina Labs Ltd Hits New 52-Week High at Rs.21.88
Rekvina Labs Ltd has surged to a fresh 52-week high of Rs.21.88, marking a significant milestone in its stock performance. This new peak reflects a sustained rally that has seen the stock deliver remarkable returns over the past three weeks, outpacing sector benchmarks despite broader market headwinds.
Read full news article
Rekvina Labs Ltd Hits New 52-Week High of Rs.21.46 on 11 Feb 2026
Rekvina Labs Ltd has surged to a fresh 52-week high of Rs.21.46, reflecting a remarkable rally that has seen the stock gain over 200% in the past 20 trading sessions. This milestone underscores the stock’s robust momentum amid a mixed broader market environment.
Read full news article Announcements 
Financial Results For The Quarter And Nine Months Ended On 31St December 2025.
09-Feb-2026 | Source : BSERegulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulation 2015 we hereby inform you that the Board of Directors of the Company at its meeting held on 06th February 2026 has inter-alia adopted and approved. 1. Financial Results for the Quarter and Nine Month ended on 31st December 2025. 2. Limited Review Report by Statutory Auditor of the Company on Standalone in-audited Financial Results for the Nine Month & Quarter ended on 31st December 2025.
Board Meeting Outcome for Outcome Of The Board Meeting Held On 06Th February 2026
06-Feb-2026 | Source : BSEDear Sir/Madam Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations 2015 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 6th February 2026 has inter-alia adopted and approved 1) The Standalone Un-Audited Financial Results for the Quarter and Nine months ended on 31st December 2025. 2) Limited Review Report by Statutory Auditors of the Company on Standalone Un-Audited Financial Results for the Quarter and Nine months ended on 31st December 2025. The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 05:32 P.M. This is for your information and record Thanking you For Rekvina Laboratories Limited
Announcement under Regulation 30 (LODR)-Change in Directorate
29-Jan-2026 | Source : BSEPursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 we hereby inform you that the Board of Directors of the Company at its meeting held on 29th January 2026 have considered and approve appointment of Mr. Jay Chintan Patel as an Additional Non-Executive Independent Director.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
Rekvina Labs Ltd has announced 5:10 stock split, ex-date: 30 Apr 14
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2021
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Surbhit Mukesh Shah (15.22%)
Viralkumar Tribhovandas Patel (4.388%)
51.98%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 75.00% vs 0.00% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -300.00% vs -50.00% in Sep 2025






